Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study Academic Article uri icon

Overview

MeSH Major

  • Brain Neoplasms
  • Glioma
  • Neoplasm Recurrence, Local
  • Quinolones
  • Salvage Therapy

abstract

  • Toxicities and pharmacokinetics differ significantly when comparing patients on or off EIAEDs. EIAEDs significantly decreased the maximum concentration, AUC(0-12 hours), and predose trough concentrations of tipifarnib. Even in the presence of EIAEDs, the levels of tipifarnib were still sufficient to potently inhibit FTase activity in patient PBMCs. The relevance of these important findings to clinical activity will be determined in ongoing studies with larger numbers of patients.

publication date

  • September 20, 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2005.10.068

PubMed ID

  • 16170172

Additional Document Info

start page

  • 6647

end page

  • 56

volume

  • 23

number

  • 27